| RAYMOND MEEHAN, 51
Pa., a former Staten Island resident and retired purchasing manager, died Saturday in St. Vincent's Hospital, Manhattan, of pancreatic cancer. Born in West Brighton, he grew up in Stapleton. Mr. Meehan moved to Washington, N.J., in 1992 before settling in Bethlehem in 2005. Mr. Meehan worked for more than 20 years as a purchasing manager for Palmer Industries, Newark, retiring in 2004. He graduated from Curtis High School and was a member of the Stewartsville (N.J.) Knights of Columbus. He enjoyed repairing old houses and landscaping. "He faced death the same way he faced life -- with courage and grace," said his sister, Aileen Connelly. Along with his sister, Aileen, also surviving are his wife of 10 years, the former Julia Geyer; two sons, Raymond Jr.
Concerned about Prostate Cancer? New Drug May Help Prevent the Disease
Healthy men who are worried about prostate cancer should consider taking a drug called finasteride daily to reduce their risk of developing the condition. Finasteride is sold by Merck as Proscar to treat swollen prostates and as Propecia to treat baldness. The recommendation especially applies for men with a normal reading on the prostate-specific antigen or PSA, test, which is considered the best indicator of the presence of a tumor. Clinical trials on the drug included only men in this category. Previous studies have also shown that the drug reduces the risk of prostate cancer, but experts are worried that it may be responsible for an increased risk of deadliest tumors. Recent analysis, however, have dismissed these worries and the American Society of Clinical Oncology and the American Urological Association recommend patients to talk to their doctor about the benefits of this drug.
Take Herbal Supplements to Retain Youth
Green may be beneficial in reducing the risk of breast cancer, prostate cancer, colon cancer and gastric cancer. They are also beneficial to maintain remission in persons with Crohn's disease, to prevent Parkinson's disease and help protect against heart disease, dental caries and kidney stones.
• Guggulipid Extract Supplements: These supplements are used for arthritis, lowering high cholesterol, atherosclerosis, nodulocystic acne, skin diseases and weight loss.
• Olive Leaf Extract Supplements: These supplements are used for fungus and yeast infections, frequent colds, asthma, vaginal yeast infections, rheumatoid arthritis, diabetes, bacterial infections, herpes, AIDS, chronic fatigue, flu and colds.
• Tumeric Extract Supplements: These supplements are beneficial for preventing rheumatoid arthritis, cancer, atherosclerosis, bursitis, genital herpes, hepatitis, HIV support, low back pain and osteoarthritis.
Singapore research organisations team up to advance drug discovery
With increased opportunities for exchanging ideas and synergising efforts, more effective and less invasive cancer treatment is now one step closer to becoming a reality. Dr. Jonathon D. Sedgwick, LSCDD Managing Director and Chief Scientific Officer, said that "discovering new, breakthrough medicines through translational and clinical research requires intensive collaborations amongst partners. This research collaboration with clinicians and scientists from NNI and SICS will bring together different expertise and resources. This fits well with Lilly's new collaborative model known as the Fully Integrated Pharmaceutical Network (FIPNet) model, and will enhance and accelerate Lilly's ability to find 'Answers That Matter'." .
Prostate screening earns award for CHS
"Our area ranks fourth in the state for incidence of prostate cancer. Local residents needed to be alerted to the facts, and get tested for prostate cancer," said Al Maghazehe, president and CEO at Capital Health. "We were very pleased with the overwhelming response to this program and that more than 300 men in our community took advantage of the free screenings." According to Rona Remstein, RN, director of Oncology Services at Capital Health, a combination of strategic advertising and public relations tactics allowed Capital Health to reach a broad spectrum of residents in the Greater Mercer and Burlington Counties, thus increasing its overall number of sign-ups. Out of 531 men registered, 310 attended one of the 11 free screenings. "Importantly, more than 15 percent of the men screened were referred for further evaluation.
Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3
Silibinin is currently under phase II clinical trial in prostate cancer patients; however, its antitumor effects and mechanisms are not completely understood. Herein, we studied the efficacy and associated mechanisms of silibinin against orthotopically growing advanced human prostate carcinoma PC-3 tumors. Athymic male mice were orthotopically implanted with PC-3 cells in prostate and 1 week later after surgical recovery were gavaged daily with silibinin (100 mg/kg body weight) for 7 weeks. Silibinin treatment reduced the lower urogenital weight (including tumor, prostate, and seminal vesicle) by 40% (P < 0.05) without any toxicity in mice. Silibinin decreased proliferating cell nuclear antigen expression and proliferating cells (P < 0.001) but increased cleaved caspase-3-positive cells (P < 0.01) and apoptotic cells (P < 0.001) and suppressed tumor microvessel density (P < 0.001) and vascular endothelial growth factor expression (P = 0.02).
Promiscuity, gonorrhea are risks for prostate cancer in men: study
Although we are unable to show that gonorrhea directly causes prostate cancer, we suspect the inflammatory effect of the gonorrhea infection may trigger pre-existing cancerous cells to multiply," says lead study author Aruna Sarma, Ph.D., assistant research scientist in the Department of Urology at U-M Medical School. In the study, 65 percent of the men with prostate cancer reported having had gonorrhea, compared to 53 percent of men without prostate cancer. Men with prostate cancer were also more likely to report being diagnosed more than once with gonorrhea, a bacterial infection transmitted through sexual intercourse. The overall rate of gonorrhea is now increasing, after a steady decline for the past two decades, according to the U.S. Centers for Disease Control and Prevention (CDC).
FDA Approves Prostate Cancer Drug
The Food and Drug Administration has approved a new drug to fight the prostate cancer. The Food and Drug Administration has approved a new drug to fight the prostate cancer. Peoria physician Dr. Joseph Banno of Midwest Urological says it holds new promise for those suffering from the late stages of the disease. The new treatment for prostate cancer involves a drug called degarelix. Over the last decade, more and more cases of prostate cancer have been found relatively early...and are treatable through radiation and chemotherapy. But—for a minority –the disease is discovered in its late stages. That's where degarelix, pronounced day–guh–RELL–ix,offers some new hope. Prostate cancer is known to grow in the presence of testosterone, so suppression of testosterone has been a treatment goal for advanced prostate cancer for many years.
John Hussman Buys Apple Inc., Target Corp., Darden Restaurants Inc
Cell Genesys' clinical programs include GVAX cancer vaccines in Phase II studies for prostate cancer and Phase I/II studies for lung cancer. Cell Genesys Inc. has a market cap of $20.83 million; its shares were traded at around $0.2495 with and P/S ratio of 15.1. Sold Out: Agilent Technologies Inc. (A) John Hussman sold out his holdings in Agilent Technologies Inc.. His sale prices were between $15.45 and $22.61, with an estimated average price of $19.3. The impact to his portfolio due to this sale was less than 0.01%. Agilent Technologies is the world?s premier measurement company and a technology leader in communications electronics life sciences and chemical analysis. Agilent has two primary business segments: Bio-Analytical Measurement and Electronic Measurement.
IsoRay, Inc. Announces Distribution Agreement with BrachySciences
Management believes this distribution agreement will enable us to increase the sales of Cesium-131 within the prostate cancer therapy market. This supports our ongoing strategy of driving sales by adding an additional outside distribution channel to augment our current sales staff. We look forward to a close working relationship with BrachySciences that will help us further penetrate the brachytherapy market." IsoRay remains committed to bringing innovative products and services to the brachytherapy market in support of our physicians. We believe that this agreement will provide our physicians greater choice and flexibility in offering their patients the newest isotope available. “BrachySciences is committed to providing the most innovative products and technologies to physicians performing prostate brachytherapy," said Jim Matons, President of BrachySciences.
|
